BridgeBio Pharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BBIO Nasdaq 2830 bridgebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Pharma, Inc.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Aug 11th, 2026 2:01 pm
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge - Aug 11th, 2026 10:45 am
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - Aug 11th, 2026 8:01 am
BridgeBio Pharma Inc (BBIO) (Q2 2026) Earnings Call Highlights: Attruby Surges 211% as Pipeline ... - Aug 10th, 2026 11:03 pm
BridgeBio Pharma, Inc. Q2 2026 Earnings Call Summary - Aug 10th, 2026 6:55 pm
BridgeBio Pharma Q2 Earnings Call Highlights - Aug 10th, 2026 4:04 pm
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates - Aug 10th, 2026 3:10 pm
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates - Aug 10th, 2026 2:01 pm
Viatris Gears Up to Report Q2 Earnings: What's in the Cards? - Aug 4th, 2026 9:37 am
BridgeBio Pharma (BBIO) Stock Looks Priced At A Premium Despite 148% Returns - Aug 4th, 2026 3:14 am
BridgeBio Pharma (BBIO) Wins FDA Review For Encaleret In ADH1 - Aug 3rd, 2026 7:11 pm
BridgeBio Pharma (BBIO) After Its $2.21b Stock Filing Is It A Buy Or Priced In - Aug 3rd, 2026 1:09 pm
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET - Aug 3rd, 2026 5:30 am
1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree. - Aug 2nd, 2026 4:15 am
Alnylam plunges as earnings deliver ‘one-two punch’ - Jul 30th, 2026 10:12 am
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy? - Jul 28th, 2026 8:00 am
FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug - Jul 23rd, 2026 11:12 am
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1 - Jul 22nd, 2026 5:30 am